Viveve Medical (VIVE) Now Covered by Analysts at Northland Securities

Equities researchers at Northland Securities assumed coverage on shares of Viveve Medical (NASDAQ:VIVE) in a research report issued to clients and investors on Friday. The brokerage set an “outperform” rating and a $8.00 price target on the stock. Northland Securities’ price objective would indicate a potential upside of 60.97% from the company’s current price.

A number of other equities analysts have also weighed in on the stock. ValuEngine lowered shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Mizuho started coverage on shares of Viveve Medical in a research report on Thursday, November 16th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Cowen set a $11.00 price objective on shares of Viveve Medical and gave the company a “buy” rating in a research report on Monday, October 23rd. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $10.00.

Viveve Medical (NASDAQ VIVE) traded down $0.22 during trading hours on Friday, hitting $4.97. 250,000 shares of the stock were exchanged, compared to its average volume of 138,267. The company has a current ratio of 3.89, a quick ratio of 3.63 and a debt-to-equity ratio of 2.72. The firm has a market capitalization of $96.55, a price-to-earnings ratio of -2.31 and a beta of -0.67. Viveve Medical has a twelve month low of $3.75 and a twelve month high of $11.16.

Viveve Medical (NASDAQ:VIVE) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.08). The firm had revenue of $4.07 million during the quarter, compared to analyst estimates of $4.10 million. Viveve Medical had a negative net margin of 257.58% and a negative return on equity of 275.77%. The business’s quarterly revenue was up 120.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.46) EPS. equities analysts expect that Viveve Medical will post -2.04 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of VIVE. Rhumbline Advisers acquired a new position in Viveve Medical during the second quarter worth approximately $110,000. JPMorgan Chase & Co. acquired a new position in Viveve Medical during the second quarter worth approximately $151,000. Virtu KCG Holdings LLC acquired a new position in Viveve Medical during the second quarter worth approximately $169,000. Schwab Charles Investment Management Inc. acquired a new position in Viveve Medical during the second quarter worth approximately $189,000. Finally, California State Teachers Retirement System acquired a new position in Viveve Medical during the second quarter worth approximately $190,000. 66.90% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Viveve Medical (VIVE) Now Covered by Analysts at Northland Securities” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/05/viveve-medical-vive-now-covered-by-analysts-at-northland-securities.html.

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply